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Comparison of Four Molecular In Vitro Diagnostic Assays for
the Detection of SARS-CoV-2 in Nasopharyngeal Specimens
Wei Zhen,a Ryhana Manji,a Elizabeth Smith,a Gregory J. Berrya,b
a

Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York, USA

b

Department of Pathology and Laboratory Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, East Garden City, New York, USA

ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was ﬁrst
discovered in December 2019 as the cause of an outbreak of pneumonia in the city
of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly nonspeciﬁc, and symptoms overlap those of other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80%
of infected individuals experience mild symptoms or are asymptomatic, confounding
efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19-positive patients. In the present study, we evaluated the analytical
sensitivity and clinical performance of the following four SARS-CoV-2 molecular
diagnostic assays granted emergency use authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time
Reverse Transcriptase (RT)-PCR Diagnostic Panel (modiﬁed CDC) assay, the Simplexa
COVID-19 Direct (Diasorin Molecular) assay, GenMark ePlex SARS-CoV-2 (GenMark)
assay, and the Hologic Panther Fusion SARS-CoV-2 (Hologic) assay. This information
is crucial for both laboratories and clinical teams as decisions on which testing platform to implement are made.
KEYWORDS COVID-19, EUA, molecular diagnostics, nasopharyngeal, real-time RT-PCR,

SARS-CoV-2

S

evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identiﬁed as the
causative agent for an outbreak of viral pneumonia that began in Wuhan, China, at
the end of 2019 (1). On 11 March 2020, the classiﬁcation of the SARS-CoV-2 epidemic
was escalated to the level of a global pandemic by the World Health Organization
(WHO) (1). The WHO has named the illness caused by SARS-CoV-2 “coronavirus disease
2019” (COVID-19). COVID-19 has since continued to spread across the globe, and as of
23 April 2020, over 2.65 million cases have been conﬁrmed in more than 200 countries
and territories, causing over ⬃185,000 deaths. At the time of writing, more than
⬃843,000 conﬁrmed COVID-19 cases and ⬃46,000 deaths had been reported in the
United States according to the Centers for Disease Control and Prevention (CDC) and
the database of the Center for System Science and Engineering (CSSE) at Johns Hopkins
University (2, 3).
SARS-CoV-2 is the seventh coronavirus known to infect humans; SARS-CoV, Middle
East respiratory syndrome-CoV (MERS-CoV), and SARS-CoV-2 can cause severe disease,
whereas seasonal coronavirus HKU1, NL63, OC43, and 229E are associated with mild
symptoms (4). Coronaviruses are members of a diverse family of large RNA viruses that
are known to be involved in zoonotic transmission between a wide variety of animals
and humans. Coronaviruses generally target epithelial cells in the respiratory and
gastrointestinal tracts, and viral shedding can occur from these sites. Infection caused
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by coronaviruses can therefore typically be transmitted through several different
routes, including the aerosol and fecal-to-oral routes, with fomites often playing an
important role in the infection cycle (5). Notably, coronaviruses possess a distinctive
morphological feature, consisting of a ring of spike proteins on the outer surface of the
virus, giving the appearance of a halo or corona. In addition to inspiring the name of
the coronavirus genus, the spike proteins are also essential for infection of host cells.
The SARS-CoV-2 spike protein recognizes and binds to human cellular receptor
angiotensin-converting enzyme 2 (ACE2) and subsequently mediates fusion of the viral
and host cell membranes, allowing the virus to gain entry (6, 7). The ACE2 receptor is
found on epithelial cells of the lungs and small intestines (8).
Infection with SARS-CoV-2 can cause mild to severe respiratory illness, and symptoms include fever, cough, and shortness of breath. However, some populations
experience severe, rapidly progressive, and fulminant disease. Among these populations are older adults and people who have serious underlying medical conditions (e.g.,
heart disease, diabetes, lung disease, and immunosuppression) (9). Unfortunately, many
elements, some intrinsic to the virus and others seasonal, have lessened the effectiveness of traditional infection control measures. The combination of high rates of
human-to-human transmission (R0 ⫽ 2.0 to 2.5), stability of the virus in aerosols and on
surfaces, the fairly nonspeciﬁc clinical presentation of COVID-19, and coincidence of the
onset of COVID-19 with the active season of other respiratory viruses (e.g., inﬂuenza
virus and respiratory syncytial virus [RSV]) in many parts of the world presents a major
challenge to efforts to stop the pandemic from spiraling into a more severe global
health emergency (9, 10).
During the early stages of the epidemic, both national and international agencies
rushed to initiate the process of mass production of test reagents and issued an
emergency use authorization (EUA) for the U.S. CDC COVID-19 real-time reverse transcriptase (RT)-PCR assay (11). Despite the collective efforts, laboratories are still facing
reagent supply shortages, lack of instrument access, an inability to perform highcomplexity testing, and increased stafﬁng needs, leaving a gap in the ability of health
care providers to rapidly diagnose and manage patients. The need to implement a
sensitive, accessible, and rapid diagnostic test for the detection of COVID-19 is clear. In
this study, we evaluated the analytical and clinical performance of four SARS-CoV-2
molecular diagnostic assays granted EUA by the FDA, including the modiﬁed CDC,
DiaSorin Molecular, GenMark, and Hologic assays. These assays are authorized for the
qualitative detection of SARS-CoV-2 in clinical specimens obtained from symptomatic
patients and were evaluated using nasopharyngeal swab specimens.
MATERIALS AND METHODS
Specimen collection and storage. Sterile nylon, Dacron, or rayon swabs with ﬂexible plastic shafts
were used to collect nasopharyngeal specimens (NPS) from symptomatic patients. After collection,
swabs were placed into 3 ml of sterile universal transport medium (UTM; various manufacturers).
Specimens were transported and tested as soon as possible after collection. Before testing, samples were
subjected to vortex mixing for 3 to 5 s and a calibrated pipette was used to transfer the specimen volume
speciﬁed by each manufacturer’s instructions for use. The samples were kept for up to 72 h at 2 to 8°C
after collection before initial testing. Following routine testing, samples were aliquoted and stored in a
freezer at ⫺80°C until comparator testing.
The New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic EUA Panel
(modiﬁed CDC assay). This assay is a modiﬁed version of the CDC 2019-Novel Coronavirus (2019-nCoV)
Real-Time RT-PCR Diagnostic EUA Panel validated by the Wadsworth Center (Albany, NY) using the same
primer and probe sets as the CDC assay for nucleocapsid gene 1 (N1) and N2 targets and the human
RNase P gene (RP) but excluding the N3 primer and probe set. A 110-l volume of patient specimen was
extracted by the use of a NucliSENS easyMAG platform (bioMérieux, Durham, NC) according to manufacturer’s instructions, with a nucleic acid elution volume of 110 l. For each specimen, three Master Mix
sets that included N1, N2, and RNase P were prepared, and 15 l of each master mix was dispensed into
appropriate wells, followed by 5 l of extracted sample. Each run also included a no-template control
(NTC), a negative extraction control, and a SARS-CoV-2-positive control. Ampliﬁcation was performed on
an Applied Biosystems 7500 Fast Dx real-time PCR system (Thermo Fisher Scientiﬁc, Waltham, MA). The
results interpretation algorithm for reporting a positive specimen requires both N1 and N2 targets to be
detected.
Simplexa COVID-19 Direct EUA (Diasorin Molecular LLC, Cypress, CA). Testing with the DiaSorin
Molecular Simplexa COVID-19 Direct EUA assay was performed according to the manufacturer’s instrucAugust 2020 Volume 58 Issue 8 e00743-20
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TABLE 1 Overview of four molecular in vitro diagnostic EUA assays used in this studya
Assay
Modiﬁed CDC
Diasorin Molecular
GenMark
Hologic
aBAL,

Sample type
NPS, OPS, sputum
NPS, NS, BAL ﬂuid
NPS
NPS, OPS

Sample vol
required (l)
110
50
200
500

Extraction
required
Yes
No
Yes (automated)
Yes (automated)

Detection
platform/system
ABI 7500 Fast Dx
LIAISON MDX
ePlex
Panther Fusion

Target region(s)
of SARS-CoV-2
N (N1 and N2)
S and ORF1ab
N
ORF1ab

Analytical sensitivity
per claim
500 copies/ml
500 copies/ml
100,000 copies/ml
1 ⫻ 10⫺2 TCID50/ml

bronchoalveolar lavage; NPS, nasopharyngeal swabs; NS, nasal swabs; OPS, oropharyngeal swabs; TCID50, 50% tissue culture infective dose.

tions for use. A 50-l volume of Simplexa COVID-19 Direct kit reaction mix (MOL4150) was added to the
“R” well of the 8-well direct ampliﬁcation disc (DAD) followed by addition of 50 l of nonextracted
nasopharyngeal swab (NPS) sample to the “SAMPLE” well. Data collection and analysis were performed
with LIAISON MDX Studio software. The assay targets two different regions of the SARS-CoV-2 genome,
including the surface (S) gene and open reading frame 1ab (ORF1ab), differentiated with
6-carboxyﬂuorescein (FAM) and JOE ﬂuorescent probes. An RNA internal control (Q670 probe) is used to
detect RT-PCR failure and/or inhibition. The results interpretation algorithm for reporting a positive
specimen requires only one of the two targets to be detected (S or ORF1ab gene).
GenMark ePlex SARS-CoV-2 assay EUA (GenMark Diagnostics, Carlsbad, CA). Testing with the
ePlex SARS-CoV-2 was performed according to the manufacturer’s instructions for use. Brieﬂy, after
vortex mixing was performed for 3 to 5 s, 200 l of the primary NPS sample was aspirated into the sample
delivery device (SDD) provided with the ePlex SARS-CoV-2 panel kit and subjected to vortex mixing once
again for 10 s. The entire volume of the SDD was dispensed into the sample loading port of the
SARS-CoV-2 test cartridge, followed by ﬁrmly pushing down the cap to securely seal the sample delivery
port. Each cartridge was bar-coded and scanned with the ePlex instrument and inserted into an available
bay. Upon the completion of the assay run, the ePlex SARS-CoV-2 report was generated. The GenMark
ePlex SARS-CoV-2 assay ampliﬁes and detects the SARS-CoV-2 virus nucleocapsid (N) gene.
Hologic Panther Fusion SARS-CoV-2 EUA (Hologic Inc., San Diego, CA). The Fusion SARS-CoV-2
assay was performed according to the manufacturer’s instructions for use. A 500-l volume of NPS was
lysed by transfer to a specimen lysis tube containing 710 l lysis buffer. The input volume per sample
for extraction is 360 l. Internal control S (IC-S) was added to each test specimen and to the controls via
working Panther Fusion capture reagent S (wFCR-S). Hybridized nucleic acid was then separated from the
specimen in a magnetic ﬁeld. After wash steps, 50 l of puriﬁed RNA was eluted. Then 5 l of eluted
nucleic acid was transferred to a Panther Fusion reaction tube already containing oil and reconstituted
master mix. The Panther Fusion SARS-CoV-2 assay ampliﬁes and detects two conserved regions of the
ORF1ab gene in the same ﬂuorescence channel. The two regions are not differentiated, and ampliﬁcation
of either or both regions results in a ﬂuorescent ROX signal. The results interpretation algorithm for
reporting a positive specimen requires only one of the two targets to be detected (the ORF1a or ORF1b
gene).
Analytical sensitivity. Limit of detection (LoD) determinations were performed using a SARS-CoV-2
synthetic RNA quantiﬁed control (SARS-CoV-2 Standard) containing ﬁve gene targets (E, N, ORF1ab,
RNA-dependent RNA polymerase [RdRP], and S genes of SARS-CoV-2) from Exact Diagnostics (catalog no.
COV019; Exact Diagnostics, Fort Worth, TX). A starting concentration of 200,000 copies/ml control was
used to generate a dilution panel. The control was diluted in Ambion RNA storage solution (catalog no.
AM7001; Thermo Fisher Scientiﬁc, Waltham, MA) and aliquoted for testing in order to obtain a maximum
of 12 replicates at the following concentrations: 20,000, 2,000, 1,000, 500, 100, 50, and 5 copies/ml. The
LoD was determined by two methods: positive-rate analysis and Probit analysis. A positive rate was
deﬁned as the lowest dilution at which all replicates gave positive test results with a 100% detection rate.
The LoD by Probit was deﬁned as the lowest detectable dilution at which the synthetic RNA quantiﬁed
control (measured in numbers of copies per milliliter) gave a positive result with a 95% probability of
detection. The ﬁnal LoD was based on results of Probit analyses and on each manufacturer’s claimed
results interpretation algorithm, which determines whether a specimen result is positive, negative, or
inconclusive on the basis of the gene targets detected.
Study design. A total of 104 nasopharyngeal specimens (88 retrospective and 16 prospective)
originally submitted during March and April of 2020 to Northwell Health Laboratories for routine
COVID-19 testing on the GenMark were selected for this study. Of the 104 specimens analyzed, 51 of the
samples were positive and 53 were negative. Retrospective frozen samples were thawed, pipetted into
separate aliquots, and immediately tested by the modiﬁed CDC, DiaSorin Molecular, and Hologic assays
in parallel. Prospective specimens were performed fresh on each platform in parallel at the time of
patient testing. The study population included patients of all ages and both genders presenting with
signs and/or symptoms of COVID-19 infection. Specimens selected for this study included positive
specimens spanning the range of positivity and also specimens with low viral loads (characterized by
high cycle threshold [CT] values). In addition, specimens were selected to represent the true positivity rate
determined by us at the time this study was performed (50% to 60%). The manufacturer’s speciﬁcations
are summarized in Table 1.
Discordant analysis. Results were considered discordant when one molecular assay did not agree
qualitatively (detected or not detected) with the other three assay results. In such cases, molecular
testing was repeated for the discordant assay.
Workﬂow evaluation. Workﬂow was evaluated by the use of a stopwatch to measure the amount
of time needed for each step being evaluated, including hands-on time (HoT), assay run time, and total
August 2020 Volume 58 Issue 8 e00743-20
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TABLE 2 Summary of limit of detection results
No. of copies/ml
(95% CI)b

No. (%) of detected replicates at indicated dilution (copies/ml)a

Target
region
N1
N2

2,000
4/4 (100)
4/4 (100)

1,000
8/8 (100)
8/8 (100)

500
7/10 (70)
10/10 (100)

100
1/10 (10)
6/10 (60)

50
0/8 (0)
3/8 (38)

5
1/4 (25)
0/4 (0)

Probit
779 ⫾ 27
356 ⫾ 20

DiaSorin Molecular

S
ORF1ab

1/1 (100)
1/1 (100)

10/10 (100)
10/10 (100)

10/10 (100)
8/10 (80)

10/10 (100)
4/10 (40)

8/8 (100)
1/8 (13)

0/4 (0)
0/4 (0)

39 ⫾ 23
602 ⫾ 28

39 ⫾ 23

GenMark

N

10/10 (100)

9/9 (100)

7/10 (70)

1/10 (10)

1/4 (25)

0/4 (0)

NAd

1,000

Hologic

ORF1ab

3/3 (100)

9/9 (100)

12/12 (100)

12/12 (100)

5/9 (56)

0/6 (0)

83 ⫾ 36

83 ⫾ 36

Molecular assay
Modiﬁed CDC

Final LoDc
779 ⫾ 27

aThe

limit of detection by positive rate for each assay is highlighted in bold.
b95% CI, upper/lower (⫾) 95% conﬁdence interval.
cThe ﬁnal LoD data were determined on the basis of each manufacturer’s results interpretation algorithm.
dNA, not applicable.

turnaround time (TAT). HoT, assay run time, and TAT were calculated using the throughput of samples
per run.
Statistical methods. The reference standard was established as a “consensus result” which was
deﬁned as the result obtained by at least three of the four molecular diagnostic assays. Positive percent
agreement (PPA), negative percent agreement (NPA), positivity rate, Kappa (), Probit, and two-sided
(upper/lower) 95% conﬁdence interval (CI) data were calculated using Microsoft Ofﬁce Excel 365 MSO
software (Microsoft, Redmond, WA). Cohen’s kappa values () were also calculated as a measure of
overall agreement, with values representing levels of agreement categorized as follows: almost perfect
(⬎0.90), strong (0.80 to 0.90), moderate (0.60 to 0.79), weak (0.40 to 0.59), minimal (0.21 to 0.39), or none
(0 to 0.20) (12, 13). Probit analyses were used for the determination of the analytical sensitivity of the
studies expressed in numbers of copies per milliliter. The dose-response 95th percentile (with 95%
conﬁdence interval [CI]) model was assessed using the Finney and Stevens calculations (14).

RESULTS
Analytical sensitivity. A serial dilution of SARS-CoV-2 control panel was tested to
determine the LoD, deﬁned as the minimum concentration with detection values of
100% by positive rate and 95% by Probit analysis. The LoD established by percent
positive rate ranged from 1,000 copies/ml by both the GenMark and the modiﬁed CDC
assays to 50 copies/ml by the DiaSorin Molecular assay (Table 2). The LoD results were
further subjected to Probit analysis. The 95% detection limit values for the CDC assay
were 779 ⫾ 27 copies/ml for the N1 gene and 356 ⫾ 20 copies/ml for the N2 gene. For
the DiaSorin Molecular assay, the 95% detection limit values were 39 ⫾ 23 copies/ml for
the S gene and 602 ⫾ 28 copies/ml for ORF1ab. For the Hologic assay, the 95%
detection limit value was 83 ⫾ 36 copies/ml for ORF1ab. Probit analysis could not be
performed for the GenMark assay (Table 2). The ﬁnal LoD values, according to the assay
results interpretation algorithm from each manufacturer, ranged from 1,000 copies/ml
by the GenMark assay to 39 ⫾ 23 copies/ml by the DiaSorin Molecular assay (Table 2).
Clinical performance of four EUA SARS-CoV-2 (COVID-19) molecular assays.
Following testing of 104 clinical specimens, the modiﬁed CDC, DiaSorin Molecular, and
Hologic EUA molecular assays demonstrated a PPA of 100% (51/51), while the GenMark
ePlex SARS-CoV-2 EUA panel showed a PPA of 96% (49/51). A NPA of 100% (53/53) was
observed for GenMark and DiaSorin Molecular, while the NPA values ranged from 98%
(52/53) for CDC to 96% (51/53) for Hologic (Table 3).
Details of discordant sample analysis results are shown in Table 4. A total of ﬁve
discordant samples were found among three of the four platforms. One false-positive
sample (sample A) had CT values of 38.9 and 39.6 the for N1 and N2 genes, respectively,
on initial testing by the modiﬁed CDC assay. After repeating extraction and retesting,
the sample was determined to be negative. Two samples (sample B and sample C) were
considered false negative by GenMark but positive by the other three methods. After
reprocessing and retesting, the GenMark assay was able to detect both samples as
positive. Two additional false-positive samples (sample D and sample E) were found by
the Hologic assay; the original samples were retested and were found to be positive
August 2020 Volume 58 Issue 8 e00743-20
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TABLE 3 Clinical performance comparison of four EUA molecular assays for the detection
of SARS-CoV-2 in nasopharyngeal swab specimens (n ⫽ 104)
No. of results by
reference standarda

Kappa ()
(ⴞ 95% CI)b,c

PPA (ⴞ 95% CI)c

NPA (ⴞ 95% CI)c

1d
52

0.98 (0.94–1)

100 (0.93–1)

98 (0.89–0.99)

51
0

0
53

1.0 (0.99–1)

100 (0.93–1)

100 (0.93–1)

GenMark
Positive
Negative

49
2e

0
53

0.96 (0.91–1)

96 (0.87–0.99)

100 (0.93–1)

Hologic
Positive
Negative

51
0

2f
51

0.96 (0.91–1)

100 (0.93–1)

96 (0.87–0.99)

Molecular assay
and result
Modiﬁed CDC
Positive
Negative

Positive

Negative

51
0

DiaSorin Molecular
Positive
Negative

aThe

reference standard was deﬁned as the result obtained from at least 3 of the 4 molecular assays.
values representing levels of agreement are categorized as follows: ⬎0.90, almost perfect; 0.80 to
0.90, strong; 0.60 to 0.79, moderate; 0.40 to 0.59, weak; 0.21 to 0.39, minimal; (0 to 0.20), none.
c⫾ 95% CI, upper/lower 95% conﬁdence interval.
dThis one sample had cycle threshold (C ) values of 38.9 and 39.6 for N1 and N2, respectively, by the CDC
T
assay.
eCycle threshold (C ) value undetermined.
T
fThese two samples had cycle threshold (C ) values of 36.2 and 38.5 by the Hologic assay.
T
bKappa

and negative, respectively. Following retesting of the ﬁve discordant samples, the
GenMark ePlex SARS-CoV-2 EUA panel showed an improvement of the PPA to 100%
(51/51). Additionally, 100% NPA (53/53) was obtained for the CDC assay, while Hologic
improved to 98% (52/53) (Table 4).
Workﬂow evaluation. HoT, run time, and overall TAT to results were assessed for
all preanalytical, analytical, and postanalytical steps for all four platforms. Results of the
workﬂow assessment are shown in Table 5. The longest HoT was the Hologic assay at
⬃2 h followed by the modiﬁed CDC assay at ⬃1 h 30 min. Very comparable HoT results
were found for DiaSorin Molecular and GenMark with times of 16 min and 12 min,
respectively. The run time averaged 90 min for modiﬁed CDC, DiaSorin Molecular, and
GenMark. Hologic was the exception, with 4 h 35 min of run time (Table 5). Overall TAT
assessment, from sample to results, showed DiaSorin Molecular with the lowest TAT to
results, followed by the GenMark, modiﬁed CDC, and Hologic assays with the highest
overall times (Table 5).
DISCUSSION
In this study, we compared four different platforms for the detection of SARS-CoV-2
in patient specimens collected during March and April of the 2020 COVID-19 outbreak
in the United States. We were able to make several observations, including LoD, overall

TABLE 4 Details of discordant sample analysis
SARS-CoV-2 molecular assay result (CT)a
Sample
ID
A
B
C
D
E
aDiscordant

Reference
standard
result
NEG
POS
POS
NEG
NEG

Modiﬁed
CDC (N1/N2)
POS (38.9/39.6)
POS (35.5/ 34.5)
POS (35.3/35.0)
NEG
NEG

DiaSorin
Molecular
(S/ORF1ab)
NEG
POS (31.9/31.8)
POS (29.3/29.9)
NEG
NEG

GenMark
NEG
NEG
NEG
NEG
NEG

Hologic
NEG
POS (35.0)
POS (33.0)
POS (36.2)
POS (38.5)

Comment
Sample assay
Sample assay
Sample assay
Sample assay
Sample assay

was
was
was
was
was

repeated
repeated
repeated
repeated
repeated

by
by
by
by
by

CDC and determined NEG
GenMark and determined POS
GenMark and determined POS
Hologic and determined POS
Hologic and determined NEG

sample results are highlighted in bold. CT, cycle threshold; ID, identiﬁer; NEG, negative; POS, positive.
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TABLE 5 Throughput and workﬂow evaluation for four EUA molecular SARS-CoV-2 assays
SARS-CoV-2
molecular assay
Modiﬁed CDC
DiaSorin Molecular
GenMark
Hologic
aNA,

Throughput (no. of
samples per run)
24
8 per disc
6 per tower
120

Input vol per sample/
elution vol
110 l/110 l
50 l/NAa
200 l/NA
360 l/50 l

HoT
(per run)
⬃1.5 h
⬍16 min
⬍12 min
⬃2.0 h

Assay
run time
⬃90 min
⬃90 min
⬃90 min
⬃4 h 35 min

User results
interpretation
Yes
No
No
No

Overall
TAT
⬃3.0 h
⬃1.8 h
⬃1.7 h
⬃6.6 h

not applicable.

workﬂow comparisons, and how each test performed in a head-to-head clinical comparison. Accurate and actionable results have been at the core of medical decisionmaking during this current outbreak, both in the inpatient and the outpatient settings.
For hospitalized patients, results are critical for clinical management as well as for
infection control and cohorting for bed management. Likewise, results are just as
critical in the outpatient setting as the basis for social distancing measures to slow the
spread of infection. To that end, false-negative results are particularly troubling, since
they inevitably lead to more exposures. TAT is also critical for allocation of limited
resources, such as the limited availability of isolation rooms and real-time cohorting
decisions. In addition, health care workers need rapid results to ensure that they are not
exposing the patients whom they are treating. Moreover, levels of personal protective
equipment (PPE) required by health care professionals also vary depending on whether
a patient is COVID-19 positive, requiring a short TAT to preserve precious resources.
Considering the transmissibility of SARS-CoV-2, which has recently been estimated to
have a basic reproduction number (R0) of 2.2, meaning that on average, each infected
person can spread the infection to an additional two persons, a false-negative result
can be devastating (15, 16). This is especially true in vulnerable patient populations
such as the elderly (especially people living in a nursing home or long-term-care
facility), the immunocompromised, and people with preexisting medical conditions
(17, 18).
Our data suggest that all four PCR methods yielded comparable results ( ⱖ 0.96);
however, we did observe a notable difference in the PPA of the methods during this
large-scale evaluation of EUA in vitro diagnostic assays. Our study showed that the
DiaSorin Molecular and Hologic Fusion assays outperformed both the modiﬁed CDC
and GenMark assays with respect to overall LoD, with GenMark having the overall
highest LoD of all four platforms evaluated. DiaSorin Molecular had the lowest LoD
(39 ⫾ 23 copies/ml), closely followed by Hologic (83 ⫾ 36 copies/ml). The modiﬁed CDC
assay showed a ﬁnal LoD of 779 ⫾ 27 copies/ml based on the results interpretation
algorithm. It is worth mentioning that this assay requires both targets to be fully
detected; thus, clinical samples falling in this concentration range would be identiﬁed
and testing repeated, potentially requiring additional TAT and laboratory labor. In
contrast, GenMark was able to detect 100% of the replicates only at 1,000 copies/ml
and was not able to reliably detect replicates below 1,000 copies/ml; thus, patient
specimens below this concentration range could potentially be missed. One important
limitation to mention is that sensitivity using Probit analysis could not be calculated for
GenMark since CT values are not available as part of the ePlex system result interpretation.
The clinical correlation was also consistent with the LoD ﬁndings, where both the
DiaSorin Molecular and Hologic assays had 100% PPA and detected all specimens
deemed positive by the consensus standard (interpretation of three of four evaluated
assays as the “gold standard”), whereas GenMark missed two positive specimens (which
were subsequently detected by GenMark upon repeat testing). DiaSorin Molecular and
GenMark showed 100% NPA, while the Hologic and CDC assays initially had two and
one discordant results, respectively. Repeat testing of these three specimens showed
that for Hologic, sample D repeated as positive a second time and was therefore
potentially a false positive and sample E was negative upon repeat testing, meaning
this result could have previously been a false positive as well. The continued discordant
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result from sample D could potentially be attributed to speciﬁcity issues, since DiaSorin
Molecular exhibited a slightly lower LoD. Repeat testing of sample A on the modiﬁed
CDC assay was negative. Considering the LoD of the modiﬁed CDC assay, coupled with
the fact that both DiaSorin Molecular and Hologic gave negative test results for sample
A, this was likely a false-positive result. While all 4 assays could reliably produce results
for most patient specimens in our study, GenMark lacked sensitivity, initially missing
two low-level-positive specimens, and this could easily have impacted patient diagnosis by missing true-positive patient results.
With respect to the HoT and TAT of the four assays in this study, the throughput and
workﬂow evaluation results are clearly shown in Table 5 and are based on lab
technologist experience in our laboratory. As a routine real-time RT-PCR assay, the
modiﬁed CDC assay requires nucleic acid extraction, master mix preparation and PCR
setup, and standard PCR ampliﬁcation, as well as interpretation of the results. This
involves several manual steps, needing about 1 h 30 min HoT and an approximate
overall TAT of 3 h for processing of 24 specimens. The DiaSorin Molecular and GenMark
assays have comparatively similar HoT and TAT, based on processing 8 samples per disc
on the DiaSorin LIAISON MDX and 6 cartridges per tower in the GenMark ePlex. Clinical
laboratories may decide to purchase additional instruments to allow testing of more
samples at a time in order to satisfy patient testing volume requirements. The Hologic
Panther Fusion platform has more of an automated workﬂow, with ﬁve samples
processed at a time after loading. The sample-to-answer time for the ﬁrst ﬁve samples
is 2 h 40 min, followed by 5 results every 5 min after loading 120 samples; the total
assay run time for 120 specimens is approximately 4 h 35 min. Note that the Hologic
platform has longer HoT, because the technologist has to load the primers, probes, and
other consumables and because 120 clinical samples have to be manually transferred
to sample lysis buffer tubes. These steps, especially the pipetting of the specimen into
the lysis tube, can be somewhat labor-intensive and time-consuming, bumping the
overall TAT for 120 specimens closer to the 7-h mark. It is important to emphasize that
each platform has its advantages. For workﬂow, TAT, and ease of use, the three
sample-to-answer platforms (DiaSorin Molecular, Hologic, and GenMark) outperformed
the modiﬁed CDC assay, which is a manual assay requiring many steps, specialized
personnel, and separate areas for processing and performing the test. The Hologic
platform is more appropriate for high-volume testing, while the DiaSorin Molecular and
GenMark systems both work well in an environment where rapid results and low-tomoderate testing volumes are required.
This study had several limitations that should be mentioned. First, this was a
single-center study, and the majority of the specimens were frozen after initial testing
on the GenMark assay. While these limitations were present, they were minimized by
the fact that the GenMark assay (which was the least sensitive platform in the analysis)
actually had a potential competitive advantage, since it was the assay initially performed on fresh specimens. Second, while the number of specimens included in the
clinical correlation was only 104, the patient samples spanned the entire range of
clinical positives (including inclusion of specimens with low viral loads) and reﬂected
our overall true positivity rate, which was between 50% and 60% during this time
period of the COVID-19 outbreak.
In summary, we have evaluated four molecular in vitro diagnostic assays for the
qualitative detection of SARS-CoV-2 in nasopharyngeal specimens. The data from our
evaluation suggest that the modiﬁed CDC, DiaSorin Molecular, Hologic, and GenMark
assays performed similarly ( ⱖ 0.96) and that all but the CDC assay can function in a
sample-to-answer capacity. The GenMark assay, however, was less sensitive and had a
higher LoD than both the DiaSorin Molecular and Hologic assays. Considering the
design of all four assays, differences that could affect assay performance could include
characteristics such as input volume of initial specimen, RNA puriﬁcation and elution
volume differences, and overall differences in gene targets. The DiaSorin Molecular
platform has a lower testing volume capability than the Hologic assay (8 specimens/
disc run versus 120 specimens loaded at once) but has a short TAT and requires less
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reagent/sample preparation. All of these parameters, along with patient care needs,
may assist clinical laboratories to identify and choose the correct testing platform that
best ﬁts their needs for the diagnosis of patients infected with this novel human
coronavirus.
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